Bioinorg Chem Appl. 2012; 2012: 210682
Li Y, Gao Z, Guo P, Li Q
Di-phenyl-di-(2,4-difluobenzohydroxamato)tin(IV)(DPDFT), the brand new metal-based arylhydroxamate antitumor complex, showed high in vivo as well as in vitro antitumor activity with relative low toxicity, but no data was reported regarding the pharmacokinetics as well as dependent toxicity. In this paper, the rapid, sensitive, as well as reproducible HPLC process in vivo regulating Diamonsil ODS column with the mixture of methanol as well as phosphoric acid in water (30:70, V/V, pH 3.0) as mobile phase was developed as well as validated for the integrity of DPDFT. The plasma was deproteinized with methanol that contained acetanilide as the inner customary (I.S.). The photodiode array detector was set during the wavelength of 228nm during room temperature as well as the linear bend over the concentration range 0.1~25gmL(-1) (r = 0.9993) was obtained. The process was used to determine the concentration-time profiles for DPDFT in the plasma after singular intravenous administration with doses of 5, 10, 15mgkg(-1) to rats. The pharmacokinetics parameter calculations as well as modeling were carried out regulating the 3p97 software. The results showed that the concentration-time curves of DPDFT in rat plasma could be propitious to two-compartment model.
hospital job training
No comments:
Post a Comment